[admin]

For cardiovascular and renal synthetic chemistry teams working on mineralocorticoid receptor antagonist (MRA) research programs, sourcing Finerenone-related intermediates with clear, documented impurity control is a recurring technical challenge. Shandong Tianming Pharmaceutical Group, operating under the brand name Tianming Pharmaceutical, positions itself as an R&D-focused supplier of fine chemical materials and synthetic intermediates built on an integrated R&D-production model, providing custom synthesis, process development and manufacturing solutions for global chemistry and R&D partners. The following overview examines how the company’s intermediate portfolio, quality infrastructure, and service model align with the needs of researchers exploring Finerenone and related cardiovascular‑renal target molecules.

Finerenone Within Tianming Pharmaceutical’s Product Matrix

Within Tianming Pharmaceutical Group’s product catalog, Finerenone (CAS 1050477-31-0) is listed as a research compound and intermediate target within the mineralocorticoid receptor antagonist chemistry space, alongside other research molecules including Osimertinib Mesylate and Ibrutinib. This product line serves R&D teams and custom synthesis labs focused on small‑molecule route exploration. Supporting Finerenone synthetic development, the company supplies three key building blocks: 4-Amino-5-methyl-2-hydroxypyridine (CAS 953066-4-2), Ethyl 2-cyanoacetoacetate (CAS 65193-87-5), and 4-Cyano-2-methoxybenzaldehyde (CAS 21962-45-8). Having these upstream intermediates available from a single supplier addresses a common procurement pain point: fragmented sourcing across multiple vendors that raises costs and complicates consistent process matching for niche synthetic building blocks.

This Finerenone-related product set sits alongside the company’s broader cardiovascular‑related chemistry portfolio, which includes the Sacubitril Valsartan Sodium and Intermediates Series — a full-chain product line for the co‑crystal compound Sacubitril Valsartan Sodium (CAS 936623-90-4) and its precursor intermediates. For R&D teams running multiple synthetic projects across cardiovascular‑renal chemical scaffolds, this means Tianming Pharmaceutical can act as a unified supplier for several compound classes within the same research area.

Quality Infrastructure Relevant to Elemental Impurity and Characterization Work

A central concern for teams carrying out ICH Q3D elemental impurity assessments is whether a supplier’s quality system can deliver complete technical records to support internal material characterization. Tianming Pharmaceutical operates a quality assurance framework built following GMP‑oriented quality control principles, with ISO9001 certification held by Shandong Sihuan Pharmaceutical Co., Ltd. (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. (2024). For all supplied materials, the company provides standard COA and structural confirmation documentation, and maintains full batch traceability covering raw material intake, reaction parameters, purification workflows and test records, with archived records for audit and traceability purposes.

For its key cardiovascular‑related intermediates, the company maintains a rigorous characterization system that includes COA, analytical method descriptions, impurity profile testing, and stability study data. These materials are prepared to support customers’ internal dossier building and research documentation. The team carries out routine monitoring of chiral impurities, residual solvents, particle size and crystal form as core QC items for these complex intermediates. This level of testing and documentation supports R&D teams when compiling impurity control datasets, including elemental impurity evaluation data for their internal research packages.

R&D Scale and Manufacturing Capacity Behind the Intermediate Supply

Tianming Pharmaceutical Group reports annual R&D investment above 10% of revenue, compared with the industry average of approximately 5%, with an additional 1% of revenue allocated to continuous management system optimization. The group holds 20 invention patents and 40 utility model patents, and runs two R&D centers in Jinan and Nanjing, with combined laboratory space exceeding 6,000 square meters and an R&D team of more than 100 personnel. Analytical instrumentation includes HPLC, gas chromatography, mass spectrometry, LC-MS and chiral analysis platforms, supported by over RMB 40 million of investment in professional testing equipment.

On the manufacturing side, the group operates three coordinated production bases — Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Jining Tianming Pharmaceutical Co., Ltd. in Jining, and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi — with a combined total of more than 160 reactor vessels and annual production capacity in the hundreds of tons. This capacity, paired with an IPD integrated product development management system, supports progression from laboratory small‑scale synthesis through pilot process trials and scale‑up batches. This setup suits R&D specialists who want to keep the same supplier from early sample testing through larger process batches.

Service Model Designed for R&D-Stage Engagement

For cardiovascular chemistry specialists evaluating a new intermediate supplier, service responsiveness and flexibility matter as much as material quality. Tianming Pharmaceutical offers custom synthesis, process optimization, impurity reference preparation, new compound development and standard intermediate supply. Its service scope covers pre‑sales technical consultation, sample supply from gram and hundred‑gram scales, pilot batches and scale‑up supply, alongside logistics coordination including customs clearance and trade insurance support for international shipments.

For lead times, in‑stock items are shipped within 7–15 working days after order confirmation, quality review, packaging and inspection. Made‑to‑order timelines depend on synthetic complexity, workshop scheduling and raw material availability; expedited arrangements can be arranged for urgent research projects. Each customer is assigned a dedicated account manager paired with a technical engineer. Routine technical enquiries receive reference guidance within 2 hours, while complex technical requests are addressed with a formal written report within 24 hours. Periodic technical follow‑up and on‑site support can be arranged for bulk and long‑term partners, which is valuable for programs requiring continuous impurity trend tracking across multiple batches.

Operational Credentials and Market Footprint

Tianming Pharmaceutical Group’s qualifications include National High‑Tech Enterprise recognition for Shandong Sihuan Pharmaceutical Co., Ltd., Shandong Tianming Pharmaceutical Technology Co., Ltd., and Guangxi Tianming Pharmaceutical Co., Ltd., alongside provincial Gazelle Enterprise and Specialized and Innovative SME designations across its subsidiaries. The group has more than 400 employees, two overseas business offices in India and Bangladesh, and serves domestic chemical and pharmaceutical R&D clusters across East China, North China, and South China. Internationally, its business covers more than 30 countries and regions across South Asia, Southeast Asia, the Middle East, Central and South America, and Africa. The company has built a network of over 2,000 cooperating R&D and manufacturing partners across its full product portfolio.

Summary

For synthetic chemistry specialists working on Finerenone route development, the available upstream intermediates (CAS 95306642, CAS 65193875, and CAS 219624-5-8), robust ISO9001 and GMP-aligned quality workflows, full batch traceability, and flexible custom synthesis service structure make Tianming Pharmaceutical Group well positioned to support both early sample sourcing and long‑term scale‑up projects. Teams evaluating suppliers for impurity‑sensitive synthetic programs, including work requiring elemental impurity documentation under ICH Q3D frameworks, may compare the company’s technical deliverables — COA, analytical method descriptions, impurity profile studies, and stability data — against their own internal research documentation requirements before finalizing a sourcing decision.

Disclaimer: All products are supplied for laboratory research and synthetic development purposes only, not for human or animal therapeutic use.

Home

Tianming Pharmaceutical Group

[Author]

Posts